Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3412272 | 0.91 | MAPK1 (0.65) | MAPK1MEN1KMT2A | |
| SCHEMBL23475180 | 0.91 | MAPK1 (0.65) | MAPK1MEN1KMT2A | |
| SCHEMBL21145974 | 0.91 | MAPK1 (0.65) | MAPK1MEN1KMT2A | |
| SCHEMBL18270113 | 0.87 | MAPK1 (0.41) | MAPK1MEN1KMT2A | |
| SCHEMBL26948154 | 0.86 | MAPK1 (0.46) | MAPK1MEN1KMT2AMAPT | |
| SCHEMBL3408677 | 0.80 | MAPK1 (0.42) | MAPK1MEN1KMT2A | |
| SCHEMBL21145975 | 0.80 | MAPK1 (0.42) | MAPK1MEN1KMT2A | |
| SCHEMBL23475183 | 0.80 | MAPK1 (0.42) | MAPK1MEN1KMT2A | |
| SCHEMBL20906278 | 0.77 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL6018054 | 0.77 | MAPK1 (0.81) | MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760755-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HOFFMANN-LA ROCHE, INC. | 2009-09-10 | — | — | US | disclosed |
| US-6573275-B1 | Insecticidal compositions comprising and to methods of combatting and controlling insect pests therewith. | SYNGENTA LIMITED (GB) | 2003-06-03 | — | — | US | disclosed |
| EP-0828739-B1 | BICYCLIC AMINES AS INSECTICIDES | SYNGENTA LTD (GB) | 2002-09-11 | — | — | EP | disclosed |
| US-6391883-B1 | INSECTICIDES | SYNGENTA LIMITED (GB) | 2002-05-21 | — | — | US | disclosed |
| US-6207676-B1 | Bicyclic amines | ZENECA LIMITED (GB) | 2001-03-27 | — | — | US | disclosed |
| EP-0828739-A1 | BICYCLIC AMINES AS INSECTICIDES | ZENECA LIMITED (GB) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037494-A1 | BICYCLIC AMINES AS INSECTICIDES | ZENECA LIMITED (GB) | 1996-11-28 | — | — | WO | disclosed |
| EP-0042365-B1 | SALTS OF ENDO-8-METHYL-8-SYN-ALKYL-8-AZONIABICYCLO-(3.2.1)-OCTANE-3-ALKYLCARBOXYLATES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1984-09-12 | — | — | EP | disclosed |
| US-4411902-A | ANTISPASMODICS | VALEAS S.P.A. (IT) | 1983-10-25 | — | — | US | disclosed |
| EP-0042365-A1 | Salts of endo-8-methyl-8-syn-alkyl-8-azoniabicyclo-(3.2.1)-octane-3-alkylcarboxylates, process for their preparation and therapeutic compositions containing them | VALEAS S.p.A. INDUSTRIA CHIMICA E FARMACEUTICA (IT) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040998-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | MAPK1 2819/4885MEN1 3890/4885KMT2A 4473/4885 |
| US-11760755-B2 | Hepatitis B antiviral agents | HAVCR2, SLC10A1, HDGF | MAPK1 1347/4885MEN1 4463/4885KMT2A 3842/4885 |
| US-20230303509-A1 | SULFONAMIDO DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | CDK2, CCNK, CCNI | MAPK1 248/4885MEN1 2859/4885KMT2A 905/4885 |
| US-20200109164-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | MAPK1 2819/4885MEN1 3890/4885KMT2A 4473/4885 |
| US-20090227570-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2A | MAPK1 3131/4885MEN1 1524/4885KMT2A 822/4885 |
| US-20240239813-A1 | KRAS INHIBITORS AND PHARMACEUTICAL USES THEREOF | KRAS, NRAS, HRAS | MAPK1 139/4885MEN1 525/4885KMT2A 2630/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | MAPK1 445/4885MEN1 1050/4885KMT2A 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.